[Research progress on N6-methyladenosine and ferroptosis in childhood combined allergic rhinitis and asthma syndrome]
- PMID: 39962790
- PMCID: PMC11838029
- DOI: 10.7499/j.issn.1008-8830.2407062
[Research progress on N6-methyladenosine and ferroptosis in childhood combined allergic rhinitis and asthma syndrome]
Abstract
Combined allergic rhinitis and asthma syndrome (CARAS) is one of the common chronic airway inflammatory diseases in children. With the development of epigenetics, research on CARAS has gradually extended from protein levels to molecular levels, such as transcription and post-transcriptional regulation. N6-methyladenosine (m6A) methylation and ferroptosis have emerged as promising research hotspots in recent years, playing crucial roles in tumors, growth and development, and allergic diseases. This paper aims to summarize the characteristics of m6A and ferroptosis, along with their roles in the onset and progression of CARAS in children, thereby providing new insights and strategies for the diagnosis and treatment of childhood CARAS.
变应性鼻炎-哮喘综合征(combined allergic rhinitis and asthma syndrome, CARAS)是儿童时期常见的慢性气道炎症性疾病之一。随着表观遗传学的发展,对CARAS的研究逐渐从蛋白质层面延伸至转录、转录后调控等微观层面。N6-腺苷酸甲基化(N6-methyladenosine, m6A)和铁死亡(ferroptosis)作为近年来十分有研究前景的热点,在肿瘤、生长发育、变应性疾病等方面均发挥着关键作用。该文旨在总结m6A和铁死亡的特点,以及它们在儿童CARAS的发生发展中的作用,从而为儿童CARAS的诊治提供新的思路和策略。.
Keywords: Allergic asthma; Allergic rhinitis; Child; Combined allergic rhinitis and asthma syndrome; Ferroptosis; N6-methyladenosine.
Conflict of interest statement
所有作者均声明无利益冲突。
References
-
- GBD Chronic Respiratory Disease Collaborators . Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017[J]. Lancet Respir Med, 2020, 8(6): 585-596. DOI: 10.1016/S2213-2600(20)30105-3. - DOI - PMC - PubMed
